Pharmafile Logo

Launch excellence

- PMLiVE

In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines today.

With a rapidly changing clinical, economic and regulatory environment, the launch of new products has catapulted the pharmaceutical industry into greater complexity and pressure than ever before. Historically, new asset launches have been a tale of two halves: a hit or miss. Between 2009 and 2017, 40% of worldwide drug launches failed to meet their 2-year sales forecasts, according to McKinsey & Company1. Taking into consideration the evolving environment, there has never been a greater need for new models to navigate the path of an asset to market.

Over the past 15 years, our clients have regularly come to us to help them execute their launch plans. Often the ask is around launch readiness and activation, with a focus on tactical execution. In this article, we discuss the need to get ahead of tactical planning and demonstrate the role of ‘pre-launch asset preparedness’, to ensure we maximise the potential of specialised medicines in this highly complex environment.

You can read the full article online here or download it so you can read it later here.

If you’re planning a launch and looking for some advice, get in touch! We’re hosting free launch-strategy clinics throughout May and June. Contact Cheryl Harrison Doyle or Clare Reynolds for more details.

cheryl.harrisondoyle@wearelucidgroup.com
07818 568882

clare.reynolds@wearelucidgroup.com
07501 989799

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

My Lucid journey from PMW to Head of Medical

Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced...

Listen, learn and lift off

In April’s PME, Danny Buckland has been talking to industry leaders about launch excellence in the featured article, Listen, learn and lift off.Buckland points out that pandemic storms have changed the...

Launch excellence

In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines...

Meet The Lucid Group Talent Team

Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your...

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we're excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...

Extraordinary lives: advancing change in rare diseases (Part 1)

Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. The global rare disease community and its supporters come together on...

My Journey into MedComms #LucidLife

I began as a medical writer after almost a decade working in medical publishing as a production editor. Whilst working in publishing, I was exposed to lots of different writing...

International Women’s Day 2022 #BreakTheBias

Today is International Women’s Day. This day is about gender equality, which, to be achieved, must involve the calling out of gender bias, discrimination and stereotyping.Individually, we're all responsible for...